99mTc-interleukin-2 scintigraphy in normal subjects and in patients with autoimmune thyroid diseases: A feasibility study

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 12, 2008, Pages 2286-2293

  Chianelli, M ^a   Mather, S J ^c   Grossman, A ^c   Sobnak, R ^c   Fritzberg, A ^d   Britton, K E ^c   Signore, A ^b,e  

^a REGINA APOSTOLORUM HOSPITAL   (Italy)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^d Poniard Pharmaceuticals Inc   (United States)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

99mTc IL2; Autoimmune thyroid diseases; Dosimetry; Infiltrating lymphocytes

Indexed keywords

CHELATING AGENT; INTERLEUKIN 2; INTERLEUKIN 2 TC 99M; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; TECHNETIUM COMPLEX; TECHNETIUM TC 99M INTERLEUKIN 2;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; BLOOD PRESSURE; BODY TEMPERATURE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DOSIMETRY; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG RETENTION; DRUG SAFETY; DRUG UPTAKE; FEASIBILITY STUDY; FEMALE; HEART RATE; HUMAN; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY; LYMPHOCYTIC INFILTRATION; MALE; PERIPHERAL LYMPHOCYTE; PLASMA CLEARANCE; RADIATION DOSE; RADIOACTIVITY; SCINTIGRAPHY; SIDE EFFECT; SPLEEN; THROMBOCYTE COUNT; THYROID DISEASE; THYROID GLAND; TISSUE DISTRIBUTION; CASE CONTROL STUDY; CLINICAL TRIAL; DRUG EFFECT; GRANULOCYTE; KINETICS; LYMPHOCYTE; METABOLIC CLEARANCE RATE; METABOLISM; SCINTISCANNING;

ADULT; AUTOIMMUNE DISEASES; CASE-CONTROL STUDIES; FEASIBILITY STUDIES; FEMALE; GRANULOCYTES; HUMANS; INTERLEUKIN-2; KINETICS; LYMPHOCYTES; MALE; METABOLIC CLEARANCE RATE; ORGANOTECHNETIUM COMPOUNDS; RADIATION DOSAGE; THYROID DISEASES; TISSUE DISTRIBUTION;

EID: 58149302556     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-008-0837-7     Document Type: Article

References (19)

1. M Chianelli SJ Mather J Martin-Comin A Signore 1997 Radiopharmaceuticals for the study of inflammatory processes. A review Nucl Med Commun 18 437 455
2. 123I-interleukin-2 and its response to diet Eur J Nucl Med 27 18 24
3. 123I-Interleukin-2 scintigraphy for the in vivo assessment of intestinal mononuclear cell infiltration in Crohn's disease J Nucl Med 41 242 249
4. M Chianelli A Signore AR Fritzberg SJ Mather 1997 The development of technetium-99m-labelled interleukin-2: a new radiopharmaceutical for the in vivo detection of mononuclear cell infiltrates in immune-mediated diseases Nucl Med Biol 24 579 586
5. BM Dean F Becker JM McNally AC Tarn G Schwartz GF Bottazzo 1986 Insulin autoantibodies in the prediabetic period: correlation with islet cell antibodies and development of diabetes Diabetologia 29 339 342
6. DK McCulloch LJ Claff SE Kahn SL Shoenfeld CJ Grenbaum RS Mauset 1990 Subclinical beta-cell dysfunction is not always progressive among first degree relatives of Type 1 diabetes: five years follow-up of the Seattle study Diabetes 39 549 556
7. M Chianelli MG Parisella C D'Alessandra F Corsetti F Scopinaro A Signore 2003 The developing role of peptide radiopharmaceuticals in the study of chronic inflammation: new techniques for novel therapeutic options Q J Nucl Med 47 256 269
8. A Signore M Chianelli C D'Alessandria A Annovazzi 2006 Receptor targeting agents for imaging inflammation/infection: where are we now? Q J Nucl Med Mol Imaging 50 236 242
9. H Ohnishi JT Chao KK Lin H Lee TM Chu 1989 Role of the kidney in metabolic change of interleukin-2 Tumour Biol 10 202 204
10. IC Abbs JR Pratt MJ Dallman SH Sacks 1993 Analysis of activated T cell infiltrates in rat renal allografts by gamma camera imaging after injection of 123-iodine-interleukin-2 Transplant Immunol 1 45 51
11. SB Cohen AP Weetman 1988 Activated interstitial and intraepithelial thyroid lymphocytes in autoimmune thyroid disease Acta Endocr 119 161 166
12. T Misaki J Konishi T Nakashima Y Iida K Kasagi K Endo T Uchiyama K Kuma K Torizuka 1985 Immunohistological phenotyping of thyroid infiltrating lymphocytes in Graves' disease and Hashimoto's thyroiditis Clin Exp Immunol 60 104 110
13. P Pozzilli C Pozzilli P Pantano M Negri D Andreani AG Cudworth 1983 Tracking of indium-111-oxine labelled lymphocytes in autoimmune thyroid disease Clin Endocrinol Oxf 19 111 116
14. R Paschke M Vogg S Swillens KH Usadel 1993 Correlation of microsomal antibodies with the intensity of the intrathyroidal autoimmune process in Graves' disease J Clin Endocrinol Metab 77 939 943
15. RS Bahn AE Heufelder 1993 Pathogenesis of Graves' ophthalmopathy N Eng J Med 329 1468 1475
16. AE Heufelder RS Bahn 1994 Modulation of Graves' orbital fibroblasts proliferation by cytokines and glucocorticoid receptor agonist Invest Ophthalmol Vis Sci 35 120 127
17. PT Postema EP Krenning R Wijngaarde PP Kooy HY Oei WA van den Bosch 1994 [111In-DTPA-d-Phe1] octreotide scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activity? J Clin Endocrinol Metab 79 1845 1851
18. KH Bohuslavizki S Oberwörhmann W Brenner J-U Eberhardt H Mönig M Clausen 1995 111In-octreotide imaging in patients with long-standing Graves' ophthalmopathy Nucl Med Commun 16 912 916
19. J Rendl R Guthoff A Schirbel D Brechtelsbauer D Schiller S Seybold 2000 (Abstract) Iodine-123-interleukin-2 (i-123-IL-2) scintigraphy in Graves' ophthalmopathy (go): a new approach to assess disease activity Endocr J 47 O 004